A Randomised, Single-blind, Placebo-controlled, Single-centre, Phase I Study in Abdominally Obese Healthy Volunteers to Evaluate Methods to Assess 11-beta-HSD1 Activity in Adipose Tissue and Related Downstream Biomarkers After Single and Repeated Oral Doses of AZD4017 for 10 Days.

Trial Profile

A Randomised, Single-blind, Placebo-controlled, Single-centre, Phase I Study in Abdominally Obese Healthy Volunteers to Evaluate Methods to Assess 11-beta-HSD1 Activity in Adipose Tissue and Related Downstream Biomarkers After Single and Repeated Oral Doses of AZD4017 for 10 Days.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2010

At a glance

  • Drugs AZD 4017 (Primary)
  • Indications Obesity
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 27 Sep 2010 Planned end date changed from 1 May 2010 to 1 May 2010 as reported by ClinicalTrials.gov.
    • 27 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top